Login
Login     |     Register     |     Recover Username/Password

General Investing

Free Cash Flow Yield Is Key Indicator in Small-Cap Investing

April 25, 2012

Focusing on companies that are statistically cheap, generate prodigious amounts of free cash flow and possess catalysts for improved operating performance that are not properly discounted by the market helps investors avoid value traps in small-cap investing, says Richard A. Giesen Jr., Founder and Chief Investment Officer of Elessar Investment Management.

“We have a dual mandate for the companies we want to own. They must be growing their enterprise in tandem with the appropriate capital structure, so a company that has been successful in meeting these objectives will be financially productive in terms of generating an attractive return on capital,” he said. “We have found the free cash flow yield to be the best indicator of future performance of a company’s stock throughout a market or economic cycle.”

Giesen likes ValueClick, Inc. (VCLK), a technology company that provides online marketing services including advertising exchanges, targeted display ads and mobile advertising. He says he expects the online advertising market to grow mid-double digits in 2012, as it takes market share from print and radio. Giesen bought the stock in 2010 at a price of $11.25, and currently the stock price is above $20. He believes ValueClick shares should trade in the mid-$20s, despite giving it a discount to its peers.

“We like the strong free cash flow generation of the company, which in turn enables them to invest in R&D and acquire complementary technologies. The company’s recent acquisitions have been very timely, especially their acquisition of Greystripe, which gives them a beachhead in the next leg of growth in online advertising, mobile advertising,” Giesen said.


TSWT - Subscribe now!

The Wall Street Transcript is a completely unique resource for investors and business researchers.

Over 20,000 CEO, Equity Analyst and Money Manager Interviews

TWST Newsletter

Weekly email with New In-Depth Interviews

Most Popular Interviews
Opportunities in Hepatitis C and Genomic Technologies
David Ferreiro

Published April 26, 2014 in Biotechnology and Pharmaceuticals

Buy ($75)
Investing in Health Care Innovation
Finny Kuruvilla

"We’re a faith-based and socially responsible investing firm"

Published May 16, 2013 in Investing in Health Care

Buy ($75)
A Health Sciences Fund with a Long-Term Focus
Mark W. Oelschlager

"The fund is about $40 million in assets"

Published May 16, 2013 in Investing in Health Care

Buy ($75)
High-Yield Canadian Power Companies
John McIlveen

Published May 14, 2013 in High-Yield Equity Securities

Buy ($75)
Most Popular Reports
Investing in Health Care

Published May 16, 2013

Topics Covered: Health Care - Electronic Health Record Adoption - Biotechnology and Pharmaceutical Investing - Biotechnology and Pharmaceuticals - Biotechnology and Pharmaceutical Companies Valuation - Platform Interoperability and Data Analytics - HITECH Act Incentives - Affordable Care Act
Buy ($175)
Internet Services

Published May 10, 2013

Topics Covered: Increased Mobile Content Traffic - Chinese Online Monetization Trends - Internet Infrastructure and Services Consolidation - Social Networking Economics -
Buy ($175)
Investing Strategies

Published May 10, 2013

Topics Covered: Investing in Financial Services - Long-Term Investing - Large Cap Investing - Value Investing - High Quality Companies - Bottom-up Investing - All-Cap Growth Investing - Investing in Emerging Markets
Buy ($175)
Top Company Interviews
TWST
Register for a Free Account to gain greater access to The Wall Street Transcript right now